Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date
Ryan Allway September 1st, 2022 News, Top News San Diego, California, Sept. 01, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy statement related to... Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )